Skip to main content

MDx/CDx Focus: First Patient Joins Arno's Phase I Onapristone Trial; G2C2 Adds PGx Education Section

Premium

Arno Enrolls First Patient in Phase I Dosing Study for Onapristone

Arno Therapeutics announced this week that it has enrolled the first patient in a Phase I dose escalation study investigating onapristone in post-menopausal women with progesterone receptor-positive breast, endometrial and other solid tumors.

Arno is developing onapristone, an anti-progestin hormone blocker, as a treatment for breast and endometrial cancers. Research suggests that onapristone works by hindering the activation of the progesterone receptor (APR), which in turn stops growth of various-types of APR-driven tumors.

Arno is developing onapristone alongside a companion test that picks out which patients are APR positive and will be most likely to respond to the drug. The company recently announced it would work with Leica Biosystems to develop the companion test for onapristone.

In the Phase I study, Arno is hoping to identify the dose that it will give to patients in Phase II safety trial for onapristone in advance endometrioid cancer patients.

The 60-patient Phase I trial being conducted by contract research organization Biotrial at various sites in France and is designed to identify the recommended Phase II dose of onapristone. In the Phase I trial, researchers will study sustained release and immediate release formulations of the drug in up to six doses.


NHGRI's G2C2 Adds PGx Educational Materials

The National Human Genome Research Institute's Genetics/Genomics Competency Center (G2C2) has added educational materials on pharmacogenomics and pharmacogenetics for pharmacists.

The NHGRI launched G2C2 in 2010. The newly added PGx materials were put together by an editorial board of pharmacists wit experience in the discipline. The PGx section includes information on Basic genetic concepts; ethical, legal and social issues; genetics and disease; and PGx implementation.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.